DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Velcade (Bortezomib) - Current Clinical Trials

 
 



Velcade Related Clinical Trials

Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma [Recruiting]

Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma [Completed]

Study on the Safety and Effectiveness of VELCADE� in the Treatment of Graft-Versus-Host Disease [Completed]

An Open-Label Study to Assess the Effect of CYP3A4 Induction on the Pharmacokinetics of VELCADE (Bortezomib) [Completed]

A Dose Escalation Study of the Histone Deacetylase Inhibitor (HDACi) JNJ 26481585 in Combination With VELCADE (Bortezomib) and Dexamethasone for Patients With Relapsed Multiple Myeloma [Completed]

Velcade and Sorafenib in Unresected or Metastatic Renal Cell Carcinoma [Active, not recruiting]

Bortezomib (Velcade) in Patients With Untreated Multiple Myeloma [Active, not recruiting]

Velcade, Melphalan, Prednisone And Thalidomide Versus Velcade, Melphalan, Prednisone in Multiple Myeloma Patients [Active, not recruiting]

Pilot Study of Velcade® in IgA Nephropathy [Recruiting]

A Study to Compare CNTO 328 (Anti-IL-6 Monoclonal Antibody) and VELCADE-Melphalan-Prednisone (VMP) With VMP Alone in Previously Untreated Multiple Myeloma Patients [Completed]

Velcade Plus ICE for Patients With Relapsed Classical Hodgkin Lymphoma [Completed]

Subcutaneous Velcade Plus Oral Melphalan and Prednisone or Plus Cycloposphamide and Prednisone or Plus Prednisone [Active, not recruiting]

Study of Velcade® and Bone Formation in Patients With Relapsed/Refractory Multiple Myeloma [Terminated]

A Post-Approval Pharmacokinetic Study of Bortezomib in Participants With Multiple Myeloma [Completed]

An Observational Study of Chinese Multiple Myeloma Patients Treated With Velcade [Completed]

Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients [Active, not recruiting]

VELCADE as Maintenance Treatment in Patients With Multiple Myeloma Following Autologous Peripheral Blood Stem Cell Transplantation (PBSCT) [Recruiting]

A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma [Active, not recruiting]

Velcade®-Melphalan Association in Autologous Stem-Cell Transplantation (ASCT) [Completed]

Phase I Using Velcade & Idarubicin in Elderly and Relapsed AML [Completed]

VELCADE� Plus Rituximab in Non Hodgkin's Follicular Lymphoma [Completed]

Velcade (Bortezomib, PS-341) and Rituximab in Relapsed/Refractory Mantle Cell and Follicular Non-Hodgkin's Lymphoma [Completed]

Phase I/II Trial of VELCADE Plus Zevalin in Patients With Relapsed or Refractory Follicular Lymphoma [Active, not recruiting]

Doxil, Gemcitabine, and Velcade (PS341) in Advanced Cancer Patients [Completed]

Study of Velcade and Temsirolimus for Relapsed or Refractory Non-Hodgkin Lymphoma [Completed]

Phase I Bortezomib (VELCADE) in Combo With Pralatrexate in Relapsed/Refractory MM [Active, not recruiting]

Belinostat and Bortezomib in Treating Patients With Relapsed or Refractory Acute Leukemia or Myelodysplastic Syndrome [Active, not recruiting]

Bortezomib Plus Prednisone for Initial Therapy of Chronic Graft Versus Host Disease [Completed]

A Study of Subcutaneous and Intravenous VELCADE in Patients With Previously Treated Multiple Myeloma [Completed]

Bortezomib (Velcade) Plus Rituximab-HyperCVAD in Patients With Mantle Cell Lymphoma [Active, not recruiting]

Bortezomib and Reduced Intensity Allogenic Stem Cell Transplantation for Lymphoid Malignancies [Active, not recruiting]

Velcade for Proliferative Lupus Nephritis [Withdrawn]

Study of Temsirolimus, Topotecan, and Bortezomib [Completed]

Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia [Active, not recruiting]

Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma [Completed]

Study of Combination Therapy With VELCADE, Doxil, and Dexamethasone (VDd) in Multiple Myeloma [Completed]

Post-Transplant Bortezomib and High Dose Cyclophosphamide as Graft-Versus-Host Disease (GVHD) Prophylaxis [Recruiting]

A Phase I/II Trial of VELCADE & Gemcitabine for Patients With Relapsed or Refractory Aggressive B- and T-cell Non-Hodgkin's Lymphoma [Terminated]

Low Dose Melphalan and Bortezomib for AML and High-Risk MDS [Completed]

Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors [Active, not recruiting]

Phase I Combination of Midostaurin, Bortezomib, and Chemo in Relapsed/Refractory Acute Myeloid Leukemia [Active, not recruiting]

Safety/Efficacy Study of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma [Recruiting]

A Pharmacokinetic Study of Bortezomib in Taiwanese Participants With Multiple Myeloma [Recruiting]

A Study of Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Untreated Multiple Myeloma and Planned for a High Dose Chemotherapy [Completed]

PS-341 Plus Carboplatin in Platinum and Taxane Resistant Recurrent Ovarian Cancer, Primary Peritoneal Cancer, and Fallopian Tube Cancer [Completed]

Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma [Completed]

Velcade, Nipent, Rituxan (VNR) in Subjects With Relapsed Follicular, Marginal Zone, and Mantle Cell Lymphoma [Terminated]

Velcade in Myelodysplastic Syndrome - Pilot Study [Terminated]

Study of Vorinostat (MK-0683) an HDAC Inhibitor, or Placebo in Combination With Bortezomib in Patients With Multiple Myeloma (MK-0683-088 AMN) [Completed]

Bortezomib for the Treatment of Refractory Chronic Graft-vs-Host Disease(cGVHD) [Active, not recruiting]

Chloroquine in Combination With VELCADE and Cyclophosphamide for Relapsed and Refractory Multiple Myeloma [Completed]

Phase 1b Lymphoma Study of AMG 655 in Combination With Bortezomib or Vorinostat [Completed]

Doxil® + Melphalan + Velcade (DMV) in Relapsed/Refractory Multiple Myeloma [Completed]

Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy [Completed]

Bortezomib and Gemcitabine in Treating Patients With Recurrent or Metastatic Nasopharyngeal Cancer [Completed]

A Phase 1 Dose Escalating Trial of Bortezomib in Combination With Lenalidomide in Patients With Myelodysplasia [Completed]

Ph II CHOP+Velcade in Mediastinal LBCL [Terminated]

A Phase II Study of Velcade® in Patients Stage IIIB OR IV Non-Small Cell Lung Cancer [Terminated]

S0601 Rituximab, Combination Chemotherapy, and Bortezomib Followed by Bortezomib Alone in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma [Active, not recruiting]

Study of the Combination of VELCADE, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma [Completed]

Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer [Completed]

Dose Escalation of Velcade Daily Dose in Patients With Solid Tumors [Completed]

Phase I Study of Bortezomib With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma [Recruiting]

Study of Alimta® (Pemetrexed) Plus VELCADE® (Bortezomib) or Alimta Alone or VELCADE Alone in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Prior Therapy [Completed]

Study of Irinotecan and Bortezomib in Children With Recurrent/Refractory Neuroblastoma [Active, not recruiting]

Velcade and Eloxatin for Patients With Malignant Pleural or Peritoneal Mesothelioma [Recruiting]

Study of Bendamustine, Velcade and Dexamethasone in the Treatment of Elderly Patients With Multiple Myeloma [Active, not recruiting]

Bortezomib (Velcade) Post Allogenic Peripheral Blood Stem Cell Transplantation for Myeloma [Completed]

PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas [Completed]

Phase I Study of Induction Therapy With VELCADE and Vorinostat in Patients With Surgically Resectable Non-Small Cell Lung Cancer [Active, not recruiting]

Preemptive Strike With Bortezomib in Multiple Myeloma Patients [Terminated]

Bortezomib for Low or Intermediate-1 Myelodysplastic Syndrome (MDS) With p65 Activation [Recruiting]

Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma [Recruiting]

Obatoclax and Bortezomib in Treating Patients With Aggressive Relapsed or Recurrent Non-Hodgkin Lymphoma [Terminated]

Lenalidomide/Bortezomib/Dexamethasone & CNTO 328 in Transplant Eligible Newly Diagnosed Multiple Myeloma (MM) [Completed]

Phase II Study of VELCADE for Relapsed or Refractory T-cell Prolymphocytic Leukemia [Withdrawn]

A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma [Recruiting]

An Efficacy and Tolerability Study of Bortezomib in Combination With Rituximab Standard Therapy in Participants With Relapsed or Refractory Follicular Lymphoma [Terminated]

A Phase 3 Study of Siltuximab or Placebo in Combination With Velcade and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma [Withdrawn]

Bortezomib in Combination With Gemcitabine and Cisplatin in Advanced or Metastatic Non-Small Cell Lung Cancer [Completed]

Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma [Recruiting]

Combination of Vorinostat and Bortezomib in Relapsed or Refractory T-Cell Non-Hodgkin's Lymphoma [Terminated]

Hemostatic Effects of VELCADE®* Treatment in Multiple Myeloma Patients [Active, not recruiting]

Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma [Active, not recruiting]

VELCADE®-BEAM and Autologous Hematopoietic Stem Cell Transplantation for Non-Hodgkin's Lymphoma, or Mantle Cell Lymphoma [Completed]

An Efficacy and Safety Study of Bortezomib in Participants Previously Treated for Multiple Myeloma With Limited Kidney Function [Terminated]

Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia [Completed]

Study of Bortezomib in Combination With Cyclophosphamide and Rituximab [Completed]

Trial of VELCADE and Rituxan as Front-line Tx for Low-grade NHL [Active, not recruiting]

PS-341 and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors [Completed]

Bortezomib to Treat Significant Complication of HSCT [Completed]

Bortezomib Plus Tacrolimus and Methotrexate to Prevent Graft Versus Host Disease (GVHD) After Mismatched Allogeneic Non-Myeloablative Blood Stem Cell Transplantation [Completed]

Comparing and Combining Bortezomib and Mycophenolate in SSc Pulmonary Fibrosis [Not yet recruiting]

Safety and Efficacy Study of Single Weekly Bortezomib in Newly Diagnosed Multiple Myeloma [Active, not recruiting]

Zevalin and Velcade in Relapsed/Refractory Mantle Cell Lymphoma [Terminated]

Bortezomib in Combination With Liposomal Doxorubicin and Dexamethasone to Treat Plasma Cell Leukemia [Recruiting]

Relapse Myeloma; Cyclofosfamide; Bortezomib; Maintenance [Completed]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017